Completed PHASE4 INTERVENTIONAL NCT00171353

A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure

A Study to Describe Vascular and Renal Effects and Safety of Valsartan 80 and 160 mg in Arterial Hypertension Patients

Sponsor: Novartis

Interventions valsartan

Updated 5 times since 2017 Last updated: Nov 7, 2011 Started: Jul 31, 2004 Primary completion: Sep 30, 2005 Completion: Sep 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00171353, this PHASE4 trial focuses on Hypertension and remains completed. Sponsored by Novartis, it has been updated 5 times since 2004, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Basel, Switzerland